Peptides GLP-1 5mg CAS：87805-34-3

**GLP-1 (Glucagon-like peptide-1)** is a peptide hormone secreted by the intestine and belongs to the glucagon-like peptide family. GLP-1 is mainly secreted by intestinal L cells when eating and is involved in regulating physiological processes such as blood sugar metabolism, appetite, and gastric emptying. It plays an important role in the treatment of diabetes (especially type 2 diabetes), and many GLP-1 receptor agonists are used in clinical treatment.

### Physical and chemical properties:

GLP-1 is a polypeptide chain consisting of 30 or 31 amino acid residues (the specific length varies by species), which is derived from the precursor of the glucagon gene. The structural characteristics of GLP-1 include:

- **Molecular weight**: approximately 3,500 Daltons (Da).

- **Amino acid sequence**: The amino acid sequence of GLP-1 consists of multiple amino acids, which have certain structural similarities with glucagon, but have different biological activities.

- **Stability**: Natural GLP-1 has a short half-life, which is mainly due to its rapid degradation by enzymes (such as endopeptidases and DPP-4 enzymes) in the blood. Therefore, natural GLP-1 is not suitable for direct use as a therapeutic drug.

### Main functions and effects:

1. **Regulate blood sugar levels**: GLP-1 reduces blood sugar levels by promoting insulin secretion (insulin dependence). When blood sugar concentration increases, GLP-1 promotes the release of insulin from pancreatic β cells and inhibits the secretion of glucagon from α cells, thereby lowering blood sugar.

2. **Delaying gastric emptying**: GLP-1 can slow down gastric emptying, prolong the residence time of food in the stomach, increase satiety, and thus help control appetite.

3. **Promote β-cell proliferation**: GLP-1 also has the effect of promoting the proliferation and survival of pancreatic β cells, which helps maintain pancreatic islet function.

4. **Suppress appetite**: GLP-1 suppresses appetite and reduces food intake by acting on the central nervous system, especially the hypothalamus.

5. **Cardiovascular effects**: GLP-1 may have a protective effect on the cardiovascular system, improve heart function, and reduce the risk of heart disease.

### Dosage and use:

The main form of GLP-1 in the treatment of type 2 diabetes is **GLP-1 receptor agonists**, which are synthetic or modified molecules of GLP-1 that control blood sugar by mimicking the effects of GLP-1. Common GLP-1 receptor agonists include **liraglutide**, **exenatide**, and **dulaglutide**.

#### Dosage:

- **Liraglutide**: The usual starting dose is 0.6 mg per day, gradually increasing to 1.8 mg (daily or once a week, depending on the patient's blood sugar level and tolerance).

- **Exenatide**: The usual starting dose is 5 micrograms once a day, gradually increasing to 10 micrograms.

- **Dulaglutide**: The usual dose is 0.75 mg to 1.5 mg once a week.

The specific dose may be adjusted depending on the type of drug, the treatment goal, and individual differences.

### Half-life and pharmacokinetics:

- **Half-life**: The half-life of natural GLP-1 is very short, about 1-2 minutes, mainly due to its rapid degradation by DPP-4 (peptidase) in the body. Therefore, GLP-1 receptor agonists are usually used in treatment, which are designed to be more stable and usually have a longer half-life. For example:

- **Liraglutide**: The half-life is about 13 hours, allowing for once-daily injections.

- **Dulaglutide**: The half-life is longer, about 5 days, so it is usually injected once a week.

- **Exenatide**: The short-acting half-life is about 2.4 hours, and the long-acting half-life is about 2.4 days.

- **Drug metabolism**: GLP-1 receptor agonists are usually excreted through the kidneys, and a small part is metabolized by the liver. Due to their long-acting nature, frequent dosing is not required.

### Cycle and Action:

- **Duration of Action**: The duration of action of GLP-1 receptor agonists can range from hours to days, depending on the stability of the drug. For example, long-acting drugs (such as dulaglutide) can maintain their effects for a week, while short-acting drugs (such as exenatide) require daily or more frequent injections.

- **Treatment Cycle**: GLP-1 receptor agonists are usually used for long-term management of diabetes, and the treatment cycle depends on the patient's condition. As treatment progresses, patients usually adjust the drug dose through blood glucose monitoring.

### Clinical Application:

GLP-1 receptor agonists are widely used to treat **type 2 diabetes**, especially when other oral hypoglycemic drugs (such as metformin, sulfonylurea drugs) are ineffective. They can not only effectively control blood sugar, but also help patients lose weight, and are a powerful tool for managing diabetes. In addition, GLP-1 receptor agonists have also shown good prospects in **obesity treatment**.

### Side effects:

Common side effects of GLP-1 receptor agonists include:

- **Gastrointestinal discomfort**: such as nausea, vomiting, diarrhea or constipation.

- **Hypoglycemia**: Hypoglycemia may occur when used in combination with other hypoglycemic drugs, especially when used in combination with insulin or sulfonylureas.

- **Risk of pancreatitis**: Long-term use of GLP-1 receptor agonists may be associated with the risk of pancreatitis, but more research is needed to confirm this.

- **Allergic reactions**: Although rare, some people may have allergic reactions to GLP-1 receptor agonists.

In general, GLP-1 and its receptor agonists play an important role in the treatment of diabetes and can effectively control blood sugar, reduce weight and improve overall metabolic status. With the progress of drug development, the clinical application areas of GLP-1 drugs are also expanding.

GLP-1 (glucagon-like peptide-1) drugs are a class of drugs used to treat type 2 diabetes and obesity. In recent years, they have been widely used in the field of diabetes and weight management. These drugs help regulate blood sugar and weight by mimicking or promoting the effects of GLP-1. The following is a detailed introduction to GLP-1 drugs, including applicable populations, working principles, usage and dosage, etc.

### 1. **Applicable population**

GLP-1 drugs are mainly suitable for the following populations:

- **Type 2 diabetes patients**: GLP-1 receptor agonists can help patients with type 2 diabetes control blood sugar, especially when oral hypoglycemic drugs (such as metformin and sulfonylurea drugs) are not effective. They have a good effect on insulin secretion, glucose metabolism, etc.

- **Obese patients**: For obese patients with metabolic problems, GLP-1 drugs can help lose weight by controlling appetite, reducing food intake, and increasing satiety.

- **Diabetic patients with cardiovascular disease**: Some GLP-1 drugs (such as liraglutide, saxagliptin, etc.) have a protective effect on the cardiovascular system and can reduce the risk of cardiovascular events.

- **Patients with insufficient diet and exercise**: For some patients who cannot control their weight through diet and exercise, GLP-1 drugs may become an effective treatment option.

### 2. **How ​​it works**

GLP-1 drugs work by simulating or increasing the effects of endogenous GLP-1. GLP-1 is a hormone secreted by the intestine, mainly secreted after eating, and regulates blood sugar and body weight through the following mechanisms:

- **Promote insulin secretion**: When blood sugar levels are high, GLP-1 promotes insulin secretion by enhancing the function of pancreatic β cells, thereby helping to lower blood sugar.

- **Inhibit glucagon secretion**: GLP-1 can inhibit the secretion of glucagon by pancreatic α cells and reduce liver gluconeogenesis, thereby further lowering blood sugar levels.

- **Delaying gastric emptying**: GLP-1 helps reduce food intake and control weight by delaying gastric emptying, increasing the time food stays in the stomach, and increasing satiety.

- **Enhancing pancreatic β-cell function and survival**: GLP-1 has a certain pancreatic β-cell protective effect and can slow down the progression of diabetes.

- **Promoting fat metabolism**: GLP-1 may also promote fat oxidation and inhibit fat accumulation, improve body fat distribution, and further promote weight loss.

### 3. **Usage and Dosage**

GLP-1 drugs have a variety of preparations, including injections and oral preparations. Common GLP-1 receptor agonists include liraglutide (such as liraglutide injection), exenatide, semaglutide, etc. Their usage and dosage are as follows:

#### 3.1 **Injection**

Most GLP-1 drugs are injections, usually injected once a week or once a day, and the specific frequency of use depends on the type of drug.

- **Semaglutide**:

- Dosage: once a week.

- Starting dose: usually starts from 0.25 mg, gradually increased to 0.5 mg or 1 mg.

- Increased dose: gradually adjusted according to the patient's tolerance and treatment effect.

- **Liraglutide**:

- Dosage: once a day.

- Starting dose: 0.6 mg, gradually increased to 1.2 mg or 1.8 mg.

- **Exenatide**:

- Dosage: twice a day or once a week, depending on the specific preparation.

- Starting dose: 0.6 mg, gradually increased to 1.2 mg.

#### 3.2 **Oral preparations**

Oral preparations such as **Oral semaglutide** are new products of GLP-1 drugs with good convenience.

- **Ogliflozin**:

- Dosage: once a day, orally, it is recommended to take on an empty stomach.

- Starting dose: 3 mg, the dose can be increased to 7 mg or 14 mg per week depending on the patient's tolerance.

### 4. **Side effects**

GLP-1 drugs are generally well tolerated, but some side effects may occur, especially in the early stages of treatment. Common side effects include:

- **Gastrointestinal symptoms**: such as nausea, vomiting, diarrhea, constipation, etc., these side effects usually decrease with continued treatment.

- **Hypoglycemia**: Although GLP-1 drugs themselves rarely cause hypoglycemia, they may increase the risk of hypoglycemia when used in combination with other hypoglycemic drugs (such as sulfonylureas, insulin).

- **Weight loss**: Although this is the desired effect for most patients, losing weight too quickly may lead to problems such as malnutrition.

- **Pancreatic problems**: Some studies have shown that GLP-1 drugs may be associated with an increased risk of pancreatitis. Although this risk is low, caution is still required when using them.

### 5. **Precautions**

- **Pregnant and lactating women**: Due to the lack of sufficient safety data, GLP-1 drugs are generally not recommended during pregnancy.

- **Patients with chronic gastrointestinal diseases**: Patients with delayed gastric emptying or gastrointestinal motility disorders may need to be cautious when using GLP-1 drugs.

- **Renal insufficiency**: Patients with renal impairment need to adjust the dose or consider changing the drug according to the doctor's guidance when using certain GLP-1 drugs.

In short, GLP-1 drugs provide an effective treatment option for the management of type 2 diabetes and obesity. They have significant effects in controlling blood sugar, reducing weight and improving the overall health of patients by promoting insulin secretion, inhibiting glucagon secretion, delaying gastric emptying and improving body weight. When using, the appropriate drug and dose should be selected according to the individual's specific situation and treatment goals.

GLP-1 (Glucagon-like peptide-1) and its benefits

GLP-1 (Glucagon-like peptide-1) is a hormone secreted by the intestines and belongs to the peptide hormone class. It plays an important role in blood sugar regulation, gastrointestinal function and appetite control. In recent years, GLP-1 drugs (such as liraglutide, semaglutide, etc.) have been widely used in the treatment of diabetes and obesity, and their benefits have been confirmed by a large number of studies. The following is a detailed introduction to the multiple benefits of GLP-1:

### 1. **Blood sugar regulation**

One of the main functions of GLP-1 is to regulate blood sugar. It works through the following mechanisms:

- **Stimulate insulin secretion**: GLP-1 promotes insulin secretion by binding to the GLP-1 receptor of pancreatic beta cells. Especially after a meal, when blood sugar rises, GLP-1 can enhance insulin secretion, thereby helping to lower blood sugar.

- **Inhibit glucagon secretion**: GLP-1 can inhibit the secretion of glucagon. Glucagon is a hormone that promotes the release of glucose from the liver, while the role of GLP-1 is to reduce its secretion, thereby preventing the liver from producing too much glucose and lowering blood sugar levels.

- **Promote insulin sensitivity**: GLP-1 can improve the efficiency of insulin action, thereby improving insulin sensitivity and helping to regulate blood sugar.

### 2. **Weight loss effect**

GLP-1 helps lose weight through several pathways:

- **Reduce appetite**: GLP-1 can reduce appetite and delay the onset of hunger by acting on the appetite center of the brain. The effect of GLP-1 makes people feel full after eating, thereby reducing food intake.

- **Slow down gastric emptying**: GLP-1 can slow down the emptying of the stomach and prolong the time that food stays in the stomach, which not only makes people feel fuller for a longer time, but also reduces the sharp fluctuations in blood sugar.

- **Increase energy expenditure**: GLP-1 drugs can indirectly increase energy expenditure by promoting fat metabolism or improving energy balance, thereby helping to lose weight.

### 3. **Cardiovascular protection**

GLP-1 not only plays a role in the management of diabetes, but also has cardiovascular protection:

- **Reducing the risk of cardiovascular disease**: Studies have found that GLP-1 receptor agonists have a protective effect on cardiovascular disease, including reducing the risk of cardiovascular events such as heart attack and stroke. This is related to its effects on improving blood sugar control, reducing weight, and lowering blood pressure.

- **Improving endothelial function**: GLP-1 helps improve the function of endothelial cells and enhances vascular relaxation, which helps maintain blood pressure stability and improve blood flow.

- **Reducing inflammatory response**: GLP-1 may reduce the risk of cardiovascular disease by reducing systemic inflammatory response. Inflammatory response is an important factor in cardiovascular diseases such as atherosclerosis.

### 4. **Gastrointestinal function regulation**

The role of GLP-1 in the gastrointestinal system cannot be ignored:

- **Slowing down gastric emptying**: GLP-1 can slow down the emptying rate of the stomach, which plays a role in controlling appetite and delaying the increase in blood sugar after a meal.

- **Promote intestinal health**: GLP-1 can promote intestinal motility, improve intestinal motility, and improve constipation symptoms. This is related to its relaxing effect on the gastrointestinal tract and the regulation of intestinal endocrine function.

### 5. **Neuroprotective effect**

Studies have shown that GLP-1 also has potential in the nervous system:

- **Improve cognitive function**: GLP-1 receptor agonists have shown the ability to promote neuronal growth and repair in animal experiments, which may have potential benefits for improving cognitive function, especially for the treatment of neurodegenerative diseases such as Alzheimer's disease.

- **Antidepressant effect**: Some studies have shown that GLP-1 also has antidepressant potential, which may be related to its effect on the brain and regulation of neurotransmitters.

### 6. **Improve lipid metabolism**

GLP-1 is also related to lipid metabolism:

- **Lower blood lipid levels**: GLP-1 receptor agonists can lower total cholesterol, low-density lipoprotein (LDL-C) and triglyceride levels in the blood, which helps improve cardiovascular health.

- **Promote fat metabolism**: GLP-1 can increase the oxidation of fatty acids and reduce fat accumulation, thereby reducing abdominal fat, indirectly helping to lose weight and improve lipid metabolism.

### 7. **Anti-diabetic effect**

In addition to its direct regulatory effect on blood sugar, GLP-1 has many positive effects on diabetes management:

- **Improve glucose tolerance**: GLP-1 receptor agonists can significantly improve glucose tolerance in patients with type 2 diabetes and help them better control postprandial blood sugar.

- **Long-term blood sugar control**: GLP-1 receptor agonists can improve the HbA1c level of diabetic patients in long-term use, which is an important indicator for diabetes management.

- **Reduce the risk of complications**: Since GLP-1 improves diabetes control, it helps reduce the risk of diabetes-related complications such as nephropathy, retinopathy, etc.

### 8. **Improve pancreatic islet function**

GLP-1 also plays an important role in the function of the pancreas:

- **Promote β-cell function**: GLP-1 can stimulate the proliferation and repair of pancreatic β-cells, which helps to enhance the function of pancreatic β-cells and insulin secretion.

- **Protect pancreatic β cells**: Studies have shown that GLP-1 has antioxidant and anti-inflammatory effects, can reduce β cell damage, and help protect pancreatic islet function.

### 9. **Clinical application**

Based on these benefits, GLP-1 receptor agonists have been widely used in clinical practice, especially in the treatment of type 2 diabetes and obesity. Common GLP-1 drugs include:

- **Liraglutide**

- **Semaglutide**

- **Exenatide**

- **Dulaglutide**

These drugs can generally help patients improve blood sugar control, lose weight, and improve overall metabolic health.

### Summary

As an important physiological hormone, GLP-1 has a variety of biological effects and therapeutic potential. It not only plays a key role in blood sugar control, but also shows significant benefits in weight loss, improving cardiovascular health, promoting neuroprotection, and improving lipid metabolism. Therefore, GLP-1 receptor agonists have become an important treatment for diabetes and obesity, and have also provided new ideas for the treatment of other metabolic diseases. As research deepens, GLP-1 may play a broader role in the prevention and treatment of more diseases.

WhatsApp/Telegram:+852 6749 2648

Gmail:lucasraws207@gmail.com

Skype：live:.cid.8f21dc7fc6621ba7

Hot Tags: peptides glp-1 5mg cas：87805-34-3, China peptides glp-1 5mg cas：87805-34-3 manufacturers, suppliers, factory, Ipamorelin CAS 170851 70 4, Sermorelin CAS 86168 78 7, Sermorelin Build muscle and improve cardiovascular function, MGF Promote muscle repair and accelerate fat burning, AOD9604 CAS 221231 10 3, Ipamorelin Protect muscle tissue